J1S-MC-JP04: A Randomized, Open-Label Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma
This research study, called J1S-MC-JP04, is for adults with Ewing's sarcoma that has returned or hasn't improved with standard treatments. It's a Phase 2 trial, meaning it's exploring how effective a new treatment combination is. Participants will receive a drug called Verzenios (abemaciclib) as tablets, along with chemotherapy drugs called irinotecan and temozolomide. The study aims to find out if this combination can stop the cancer from getting worse for longer periods. Doctors will regularly check the cancer's size and progress using scans, and they'll compare the results of different treatment groups. This study is designed to help find better ways to treat Ewing's sarcoma.
Auf einen Blick
Worum geht es in dieser Studie?
This study is looking into a new treatment for Ewing's sarcoma, a type of cancer that often affects bones or soft tissue. Specifically, it's for people whose cancer has either come back after treatment or hasn't responded to previous treatments. The study aims to see if combining a newer drug called Verzenios (which is the brand name for abemaciclib) with two standard chemotherapy drugs, irinotecan and temozolomide, can be an effective way to manage the cancer.
Verzenios is a type of targeted therapy. This means it's designed to specifically block certain signals that help cancer cells grow and divide. By combining it with irinotecan and temozolomide, which are traditional chemotherapy drugs that work in different ways to kill cancer cells, doctors hope to achieve a stronger effect against the cancer than with previous treatments alone.
The main goal of this particular study is to measure how long people on this combination treatment live without their cancer getting worse. This is called "progression-free survival." Doctors will carefully monitor participants using regular scans to see if the cancer shrinks, stays the same, or grows. This research is important because it could lead to new and better treatment options for Ewing's sarcoma patients in the future.
Wichtige Erkenntnisse
- This study explores a new combination treatment for Ewing's sarcoma that has returned or not responded to previous therapies.
- It combines a targeted drug (Verzenios/abemaciclib) with two chemotherapy drugs (irinotecan and temozolomide).
- The main goal is to see how long people live without their cancer getting worse.
- It's a Phase 2 trial, focused on understanding how well this new treatment works.
- Participants will have regular check-ups, blood tests, and scans.
Wer könnte berechtigt sein?
This study is open to adults who are 18 years old or older. Both men and women can take part.
To be eligible, you must have Ewing's sarcoma that has either come back after previous treatment or has not responded to the treatments you've had. The doctors will need to review your medical history and test results to confirm this.
There will be other health checks and criteria that the study doctors will need to discuss with you to make sure it's safe and appropriate for you to participate.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you been diagnosed with Ewing's sarcoma?
- Has your Ewing's sarcoma come back, or has it not responded to your previous treatments?
- Are you able to take daily tablets and attend regular hospital visits for treatments and assessments?
- Are you comfortable knowing that you will be receiving an experimental treatment combination?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you will receive regular doses of the medication. This includes taking Verzenios tablets by mouth every day, and also receiving the chemotherapy drugs irinotecan and temozolomide, which might be given as an infusion (into a vein) or as tablets, depending on the drug. The study is "open-label," which means both you and your doctors will know which treatments you are receiving.
You will have regular hospital visits for check-ups, blood tests, and scans (like MRI or CT scans) to monitor your health and see how the cancer is responding to the treatment. These visits will help doctors track the size of your cancer and check for any side effects. The exact schedule of visits and treatments will be explained to you in detail by the study team. You will likely continue on the treatment for as long as it is working and you are tolerating it well, or until the study concludes, with regular follow-up appointments even after treatment ends.
Potenzielle Risiken und Vorteile
Standorte (4)
- —UnbestätigtItalien
- —UnbestätigtSpanien
- —UnbestätigtFrankreich
- —UnbestätigtDeutschland
Häufige Fragen
What is Ewing's sarcoma?
Ewing's sarcoma is a rare type of cancer that typically affects bones or soft tissue, usually in children and young adults.
What is a 'Phase 2' study?
A Phase 2 study is a stage in clinical research where doctors test a new treatment on a larger group of people to see if it works and to further check its safety.
What is Verzenios (abemaciclib)?
Verzenios is a targeted therapy drug that works by blocking certain proteins that help cancer cells grow and divide. It's taken as a tablet.
What are irinotecan and temozolomide?
These are chemotherapy drugs that work by stopping cancer cells from growing and dividing, helping to shrink or control the cancer.
Werde ich wissen, welche Behandlung ich bekomme?
Yes, this is an "open-label" study, meaning both you and your doctors will know exactly which medicines you are receiving.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.